$Viking Therap(VKTX.US) rose significantly today, as its weight-loss drug pipeline took another step forward – its second candidate, VK3019, just entered a Phase 1 first-in-human single ascending dose trial, while the Phase 3 trials for its main drug, VK2735 (both oral and injectable), are also progressing.
Whenever there's a new data point in the GLP-1 space, $Viking Therap(VKTX.US) has always shown high volatility. This rally is more about pipeline expectations being realized rather than pure sentiment.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
